Lawyers wrapping up the final details of a $200 million California class action settlement over hormone replacement therapy drugs have found a novel solution for a nice problem to have: what to do with all the leftover money.

Even after the standard 25% in attorney fees—about $50 million—and more than $1 million in expenses and notice costs, the settlement with the now-defunct Wyeth Inc., which made Premarin, Prempro and Premphase, leaves about $142 million in residual funds, according to the lawyers. Starting next year, that money will go to research and education to promote women’s health.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]